Zobrazeno 1 - 10
of 10
pro vyhledávání: '"Astero Klabatsa"'
Autor:
Dario Barbone, Carlo Follo, Nohemy Echeverry, Victor H Gerbaudo, Astero Klabatsa, Raphael Bueno, Emanuela Felley-Bosco, V Courtney Broaddus
Publikováno v:
PLoS ONE, Vol 10, Iss 8, p e0134825 (2015)
Malignant pleural mesothelioma is a highly chemoresistant solid tumor. We have studied this apoptotic resistance using in vitro and ex vivo three-dimensional models, which acquire a high level of chemoresistance that can be reduced by PI3K/mTOR inhib
Externí odkaz:
https://doaj.org/article/c32e69aebb8b4def990b7e0dba22f2cf
Autor:
Sara Busacca, Alex D Chacko, Astero Klabatsa, Kenneth Arthur, Michael Sheaff, Dario Barbone, Luciano Mutti, Vignesh K Gunasekharan, Julia J Gorski, Mohamed El-Tanani, V Courtney Broaddus, Giovanni Gaudino, Dean A Fennell
Publikováno v:
PLoS ONE, Vol 8, Iss 6, p e65489 (2013)
Based on promising preclinical efficacy associated with the 20S proteasome inhibitor bortezomib in malignant pleural mesothelioma (MPM), two phase II clinical trials have been initiated (EORTC 08052 and ICORG 05-10). However, the potential mechanisms
Externí odkaz:
https://doaj.org/article/5d8e2afc12944741abf07215256c251c
Autor:
Sara Busacca, Alex D. Chacko, Astero Klabatsa, Kenneth Arthur, Michael Sheaff, Dario Barbone, Luciano Mutti, Vignesh K. Gunasekharan, Julia J. Gorski, Mohamed El-Tanani, V. Courtney Broaddus, Giovanni Gaudino, Dean A. Fennell
Publikováno v:
PLoS ONE, Vol 8, Iss 12 (2013)
Externí odkaz:
https://doaj.org/article/9e1ffb25bffe4dc6bf2b6d0d3d021472
Autor:
Ritu R. Gill, Thorsten Persigehl, Samuel G. Armato, Astero Klabatsa, M. Feigen, Zacariah E. Labby, Johan Coolen
Publikováno v:
Lung Cancer. 82:190-196
Imaging of malignant pleural mesothelioma (MPM) is essential to the diagnosis, assessment, and monitoring of this disease. The complex morphology and growth pattern of MPM, however, create unique challenges for image acquisition and interpretation. T
Autor:
Jin-Li Luo, Kyle B. Matchett, Mohamed El-Tanani, Marion MacFarlane, Astero Klabatsa, Ian R. Powley, D.A. Proia, M. Sequeira, J. Le Quesne, Dean A. Fennell, Edward W. P. Law, Sara Busacca, J.H. Pringle, J.M. Edwards
Publikováno v:
Busacca, S, Law, EWP, Powley, IR, Proia, DA, Sequeira, M, Le Quesne, J, Klabatsa, A, Edwards, JM, Matchett, KB, Luo, JL, Pringle, JH, El-Tanani, M, McFarlane, M & Fennell, DA 2016, ' Resistance to HSP90 inhibition involving loss of MCL1 addiction ', Oncogene, vol. 35, pp. 1483-1492 . https://doi.org/10.1038/onc.2015.213
Busacca, S, Law, E W P, Powley, I R, Proia, D A, Sequeira, M, Le Quesne, J, Klabatsa, A, Edwards, J M, Matchett, K B, Luo, J L, Pringle, J H, El-Tanani, M, MacFarlane, M & Fennell, D A 2016, ' Resistance to HSP90 inhibition involving loss of MCL1 addiction ', Oncogene, vol. 35, no. 12, pp. 1483-1492 . https://doi.org/10.1038/onc.2015.213
Oncogene
Busacca, S, Law, E W P, Powley, I R, Proia, D A, Sequeira, M, Le Quesne, J, Klabatsa, A, Edwards, J M, Matchett, K B, Luo, J L, Pringle, J H, El-Tanani, M, MacFarlane, M & Fennell, D A 2016, ' Resistance to HSP90 inhibition involving loss of MCL1 addiction ', Oncogene, vol. 35, no. 12, pp. 1483-1492 . https://doi.org/10.1038/onc.2015.213
Oncogene
Inhibition of the chaperone heat-shock protein 90 (HSP90) induces apoptosis, and it is a promising anti-cancer strategy. The mechanisms underpinning apoptosis activation following HSP90 inhibition and how they are modified during acquired drug resist
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::84ec014309d79dd2760ee3ecf10f79b6
https://pure.qub.ac.uk/en/publications/resistance-to-hsp90-inhibition-involving-loss-of-mcl1-addiction(f119b81e-e804-440d-a7c6-a941ed519613).html
https://pure.qub.ac.uk/en/publications/resistance-to-hsp90-inhibition-involving-loss-of-mcl1-addiction(f119b81e-e804-440d-a7c6-a941ed519613).html
Autor:
Carlo Follo, V. Courtney Broaddus, Victor H. Gerbaudo, Nohemy Echeverry, Dario Barbone, Emanuela Felley-Bosco, Astero Klabatsa, Raphael Bueno
Publikováno v:
PLoS ONE
PLoS ONE, Vol 10, Iss 8, p e0134825 (2015)
PLoS ONE, Vol 10, Iss 8, p e0134825 (2015)
Malignant pleural mesothelioma is a highly chemoresistant solid tumor. We have studied this apoptotic resistance using in vitro and ex vivo three-dimensional models, which acquire a high level of chemoresistance that can be reduced by PI3K/mTOR inhib
Publikováno v:
Histopathology. 60:1164-1166
Autor:
Vicky Goh, Loic Lang-Lazdunski, Astero Klabatsa, Sally F. Barrington, Sugama Chicklore, Gary Cook
Publikováno v:
Klabatsa, A, Chicklore, S, Barrington, S F, Goh, V, Lang-Lazdunski, L & Cook, G J R 2014, ' The association of (18)F-FDG PET/CT parameters with survival in malignant pleural mesothelioma ', European Journal of Nuclear Medicine and Molecular Imaging, vol. 41, no. 2, pp. 276-282 . https://doi.org/10.1007/s00259-013-2561-1
PurposeMalignant pleural mesothelioma (MPM) is a disease with poor prognosis despite multimodal therapy but there is variation in survival between patients. Prognostic information is therefore potentially valuable in managing patients, particularly i
Autor:
Tim Crook, Frances R. Balkwill, Paul Smith, Robin M. Rudd, Peter W. Szlosarek, Arben Pallaska, Jeremy P.C. Steele, Astero Klabatsa, Matthew J. Grimshaw, Michael Sheaff, Dean A. Fennell
Publikováno v:
Clinical cancer research : an official journal of the American Association for Cancer Research. 12(23)
Purpose: Malignant pleural mesothelioma (MPM) is an increasing health burden on many societies worldwide and, being generally resistant to conventional treatment, has a poor prognosis with a median survival of Experimental Design: Initially, we docum
Autor:
Astero Klabatsa, Robin M. Rudd, Michael Sheaff, Dean A. Fennell, Jeremy P.C. Steele, Jonathan Shamash, M.T. Evans
Publikováno v:
Lung Cancer. 41:S221